VPA10894/004/001

Alfamox LA 150 mg/ml Suspension for Injection

Variation	Summary	Date
Vet - F.I.d.1 c)	VRA-R - Vet - F.I.d.1 c) - - Vet - F.I.d.1 c) - Change in the re-test period/storage period of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - Extension or introduction of a re-test period/storage period supported by real time data	21/10/26
Vet - F.III.1 a) 1.	VRA-R - Vet - F.III.1 a) 1. - - Vet - F.III.1 a) 1. - Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability - For an active substance, For a starting material/reagent/intermediate used in the manufacturing process of the active substance, For an excipient - European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. - New certificate for a non-sterile active substance that is to be used in a sterile medicinal product, where mwater is used in the last steps of the synthesis and the material is not claimed to be endotoxin free	21/10/26
Vet - B47 a)	VNRA - Vet - B47 a) - - Vet - B47 a) - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State: change of specification(s) of a former non EU Pharmacopoeial active substance, excipient or active substance starting material to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State	07/09/26
Vet - F.I.d.1 c)	VRA-R - Vet - F.I.d.1 c) - - Vet - F.I.d.1 c) - Change in the re-test period/storage period of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - Extension or introduction of a re-test period/storage period supported by real time data	24/06/26
Vet - F.III.1 a) 1.	VRA-R - Vet - F.III.1 a) 1. - - Vet - F.III.1 a) 1. - Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability - For an active substance, For a starting material/reagent/intermediate used in the manufacturing process of the active substance, For an excipient - European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. - New certificate for a non-sterile active substance that is to be used in a sterile medicinal product, where mwater is used in the last steps of the synthesis and the material is not claimed to be endotoxin free	24/06/26
Vet - B44 b)	VNRA - Vet - B44 b) - - Vet - B44 b) - Submission of a Ph. Eur. CEP for:— active substance;— starting material,	23/02/26

	reagent or intermediate used in the manufacturing process of the active substance; — excipient - New cerificate	
Vet - F.II.e.5 a)	VRA-R - Vet - F.II.e.5 a) - a) Change in the number of units (e.g. tablets, ampoules, etc.) in a pack outside the range of the currently approved pack sizes - F.II.e.5 a) Quality Changes - Container closure system -Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack outside the range of the currently approved pack sizes	15/07/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	12/11/24
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	06/02/24
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	05/09/23
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a)	14/08/23

	Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	11/08/23
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	09/08/23
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	29/06/23